---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-150555"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:26:30.553090+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Kymera appoints Jeremy Chadwick as COO; base salary $480K, equity grants

## Summary
- Jeremy Chadwick, Ph.D., appointed COO effective May 22, 2023; previously SVP at Takeda.
- Chadwick receives $480,000 annual base salary, target bonus 40% of base, plus benefits.
- Chadwick granted option for 200,000 shares (4-year vest) and RSUs for 33,333 shares (annual vest).

## SEC filing metadata
- accession: 0001193125-23-150555
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312523150555/0001193125-23-150555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312523150555/d434201d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-150555
- JSON: https://secwatch.observer/filing/0001193125-23-150555.json
- Plain text: https://secwatch.observer/filing/0001193125-23-150555.txt

## Key facts
- Executive change
  Jeremy Chadwick, Ph.D. was appointed as Chief Operating Officer at Kymera Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On May 22, 2023, Kymera Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer effective as of May 22, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312523150555/0001193125-23-150555-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.